Rezera Inc. filed Amendment No. 2 to its Form S-1 registration statement with the SEC on November 9, 2026, covering a proposed initial public offering of 16,666,667 shares of common stock at a preliminary price range of $11.00 to $13.00 per share on the Nasdaq Global Market under the symbol "RZRA."

Key Highlights

  • Share count: Rezera is offering 16,666,667 shares of common stock in this initial public offering.
  • Price range: The preliminary offering price is between $11.00 and $13.00 per share, with a midpoint of $12.00.
  • GSK interest: Glaxo Group Limited, an affiliate of GSK plc, has indicated an interest in purchasing up to 2,083,333 shares, representing up to $25.0 million at the $12.00 midpoint price, or approximately 10% of common stock outstanding after closing.
  • Overallotment option: Underwriters have been granted a 30-day option to purchase up to 2,500,000 additional shares.
  • GSK agreement: In November 2026, Rezera entered into a right of first negotiation and clinical advisory board agreement with GSK.
  • Company classification: Rezera is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under U.S. federal securities laws.
  • Industry classification: The company carries Primary Standard Industrial Classification Code 2834, covering pharmaceutical preparations.

Rezera's IPO Structure, GSK Partnership, and Pharmaceutical Focus

According to the filing, Rezera Inc. is a Delaware-incorporated company headquartered at 265 Franklin Street, Suite 1702, Boston, MA, led by President and Chief Executive Officer Geoffrey McDonough, M.D. The company falls under SIC Code 2834, which covers pharmaceutical preparations, indicating its operations are centered on drug development and related activities. The filing designates Rezera as an emerging growth company, meaning it is subject to reduced public company disclosure standards as permitted under applicable U.S. federal securities laws.

The prospectus discloses that joint bookrunners for the offering are Jefferies, TD Cowen, and Cantor, with Wedbush PacGrow acting as lead manager. The filing notes that Registration No. 333-299571 applies to this offering, and this amendment is the second filed since the original registration statement. The filing states the offering is contingent upon Rezera's common stock being listed on the Nasdaq Global Market under the ticker "RZRA," for which the company said it has applied and believes it will meet listing standards upon completion of the offering.

The filing discloses that Glaxo Group Limited, affiliated with GSK plc, has indicated an interest in purchasing up to 2,083,333 shares at the initial public offering price, representing an aggregate of up to $25.0 million based on the assumed $12.00 midpoint. The prospectus notes that "indications of interest are not binding agreements or commitments to purchase," and that GSK may ultimately purchase more, fewer, or no shares. Concurrently, the company entered into a right of first negotiation and clinical advisory board agreement with GSK in November 2026, as described in the Business section of the prospectus. The filing also cautions that "investing in our common stock involves a high degree of risk," directing readers to the Risk Factors section beginning on page 15, and contains forward-looking statements that are subject to the company's cautionary language as described in the prospectus.

What Was Disclosed

Rezera Inc. filed Amendment No. 2 to its S-1 registration statement on November 9, 2026, disclosing a proposed IPO of 16,666,667 shares at $11.00 to $13.00 per share on NASDAQ:RZRA, alongside a strategic indication of interest from GSK affiliate Glaxo Group Limited of up to $25.0 million.